COVID-KOSHA
Home
Help
(current)
Comment
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
;
High priority articles (R1, Most articles most likely to be relevant):
Second priority articles (R2, Moderate portion of articles likely to be relevant):
Other articles (R3, Lesser portion of articles likely to be relevant):
Articles Not Curated -
Drug Studies-in vitro
Last updated: 2024 Jul 18
Total hit(s): 1132
S.No.
PMID
Ascending order
Descending order
Title
Ascending order
Descending order
Journal Name
Ascending order
Descending order
Publish Date
Ascending order
Descending order
Impact Factor
Ascending order
Descending order
Citations
Ascending order
Descending order
1
38086763
Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies.
J Enzyme Inhib Med Chem
2024 Dec
8.6
1
2
38916498
"Outlaw" mutations in quasispecies of SARS-CoV-2 inhibit replication.
Emerg Microbes Infect
2024 Dec
5.84
1
3
39522531
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
Lancet Infect Dis
2024 Nov 7
21.77
1
4
39522287
Dexamethasone-loaded chitosan-decorated PLGA nanoparticles: A step forward in attenuating the COVID-19 cytokine storm?
Colloids Surf B Biointerfaces
2024 Nov 5
1
5
39541564
Discovery of Chalcone Derivatives as Bifunctional Molecules with Anti-SARS-CoV-2 and Anti-inflammatory Activities.
J Nat Prod
2024 Nov 14
1
6
39535926
AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors.
J Chem Inf Model
2024 Nov 13
4.04
1
7
39102773
Engineering a NanoBiT biosensor for detecting angiotensin-converting enzyme-2 (hACE2) interaction with SARS-CoV-2 spike protein and screening the inhibitors to block hACE2 and spike interaction.
Biosens Bioelectron
2024 Nov 1
9.52
1
8
39545673
Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID-19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity.
Immun Inflamm Dis
2024 Nov
2.28
1
9
39424074
Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.
Antiviral Res
2024 Nov
4.12
1
10
39379362
Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors.
Nat Commun
2024 Oct 8
11.8
1
11
39398138
Inhibition of the SARS-CoV-2 Non-structural Protein 5 (NSP5) Protease by Nitrosocarbonyl-Bases Small Molecules.
ACS Omega
2024 Oct 8
2.55
1
12
39383977
Fluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2.
Eur J Pharm Biopharm
2024 Oct 7
1
13
39470901
IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma.
Discov Oncol
2024 Oct 29
1
14
39468199
A single-center analysis of clonal transmission of carbapenem-resistant Acinetobacter baumannii among intensive care unit patients during the COVID-19 pandemic.
Sci Rep
2024 Oct 29
4.12
1
15
39414952
A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective.
Sci Rep
2024 Oct 16
4.12
1
16
39423875
Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial.
J Infect
2024 Oct 16
5.1
1
17
39415027
Immunomodulatory effect of IFN-gamma licensed adipose-mesenchymal stromal cells in an in vitro model of inflammation generated by SARS-CoV-2 antigens.
Sci Rep
2024 Oct 16
4.12
1
18
39387584
Mutation of a highly conserved isoleucine residue in loop 2 of several beta-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental for replication.
J Virol
2024 Oct 10
4.16
2
19
39357326
Identification of nitrile-containing isoquinoline-related natural product derivatives as coronavirus entry inhibitors in silico and in vitro.
Biomed Pharmacother
2024 Oct 1
3.83
1
20
39373132
Detection of Neutralizing Antibodies in Serum Samples Using a SARS-CoV-2 Pseudotyped Virus Assay.
Curr Protoc
2024 Oct
1
21
39400381
The SARS-unique domain (SUD) of SARS-CoV-2 nsp3 protein inhibits the antiviral immune responses through the NF-kappaB pathway.
J Med Virol
2024 Oct
2.07
1
22
39031747
Phytoconstituents of Citrus limon (Lemon) as Potential Inhibitors Against Multi Targets of SARS-CoV-2 by Use of Molecular Modelling and In Vitro Determination Approaches.
ChemistryOpen
2024 Oct
1
23
39386278
Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021-September 2023.
Can Commun Dis Rep
2024 Oct
- n/a -
1
24
39246209
Phytoconstituents as modulator of inflammatory pathways for COVID-19: A comprehensive review and recommendations.
Phytother Res
2024 Sep 9
7.5
1
25
39240093
Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
Antimicrob Agents Chemother
2024 Sep 6
4.68
1